摘要
Abstract
The incidence of invasive fungal infections is increasing year over year. In addition, invasive fungal infections is a disease which has high mortality and costs a great deal of expenses. Micafungin is a kind of echinocandin antifungal drug and is efficient for treatment of Candida and Aspergillus infections. Pharmacoeconomic analysis of micafungin versus fluconazole, liposomal amphotericin B and caspofungin for prevention and treatment of invasive fungal infections suggests that micafungin is a more cost-effective drug, which gives guidance to clinical administration to some extent.关键词
药物经济学/侵袭性真菌感染/米卡芬净/氟康唑/两性霉素B脂质体/卡泊芬净Key words
Pharmacoeconomics/invasive fungal infections/micafungin/fluconazole/liposomalamphotericin B/caspofungin分类
医药卫生
